Literature DB >> 10733095

Human mast cell migration in response to members of the transforming growth factor-beta family.

N Olsson1, E Piek, P ten Dijke, G Nilsson.   

Abstract

Mast cells are known to accumulate at sites of inflammation, however, the chemotaxins involved remain largely undefined. Transforming growth factor-beta (TGF-beta) isoforms regulate numerous cellular functions, including cell growth and differentiation, formation of extracellular matrix, and the immune response. In this study we have compared the potency of different members of the TGF-beta family as human mast cell chemotaxins, and analyzed the expression of TGF-beta binding proteins on human mast cells. We were able to demonstrate that the maximal chemotactic response was attained at approximately 40 fM for the three TGF-beta isoforms, with TGF-beta3 being more effective than TGF-beta1 and TGF-beta2 at this concentration. This effect was observed in both the HMC-1 human mast cell line and in cultured primary mast cells. In addition, TGF-beta1, TGF-beta2, and less efficiently, TGF-beta3 inhibited the proliferation of HMC-1 cells. The migratory response is probably mediated through interaction with the TGF-beta serine/threonine type I and II receptors that were found to be expressed on the cells. No expression of TGF-beta type III receptor, endoglin, or the endothelial TGF-beta type I receptor ALK-1 could be detected. These results provide evidence that TGF-beta isoforms are highly potent chemotaxins for human mast cells and can play an important role in the recruitment of mast cells in inflammatory reactions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10733095     DOI: 10.1002/jlb.67.3.350

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  31 in total

1.  TGF-β1 Suppresses IL-33-Induced Mast Cell Function.

Authors:  Victor S Ndaw; Daniel Abebayehu; Andrew J Spence; Patrick A Paez; E Motunrayo Kolawole; Marcela T Taruselli; Heather L Caslin; Alena P Chumanevich; Anuya Paranjape; Bianca Baker; Brian O Barnstein; Tamara T Haque; Kasalina N Kiwanuka; Carole A Oskeritzian; John J Ryan
Journal:  J Immunol       Date:  2017-06-21       Impact factor: 5.422

2.  Activin A: a potential therapeutic target for characterizing and stopping joint pain early in rheumatoid arthritis patients.

Authors:  Fei Dong; Xijing He
Journal:  Inflammation       Date:  2014-02       Impact factor: 4.092

3.  ADAM10 is required for SCF-induced mast cell migration.

Authors:  Travis W Faber; Nicholas A Pullen; Josephine F A Fernando; Elizabeth Motunrayo Kolawole; Jamie J A McLeod; Marcela Taruselli; Kathryn L Williams; Kevin O Rivera; Brian O Barnstein; Daniel H Conrad; John J Ryan
Journal:  Cell Immunol       Date:  2014-05-21       Impact factor: 4.868

4.  Transforming growth factor-β3 (TGF-β3) knock-in ameliorates inflammation due to TGF-β1 deficiency while promoting glucose tolerance.

Authors:  Bradford E Hall; Umesh D Wankhade; Joanne E Konkel; Karthik Cherukuri; Chandrasekharam N Nagineni; Kathleen C Flanders; Praveen R Arany; Wanjun Chen; Sushil G Rane; Ashok B Kulkarni
Journal:  J Biol Chem       Date:  2013-09-20       Impact factor: 5.157

5.  Regulation of T-cell interaction with fibronectin by transforming growth factor-beta is associated with altered Pyk2 phosphorylation.

Authors:  A Brill; S Franitza; O Lider; R Hershkoviz
Journal:  Immunology       Date:  2001-10       Impact factor: 7.397

6.  Transforming growth factor-{beta}1 modulates responses of CD34+ cord blood cells to stromal cell-derived factor-1/CXCL12.

Authors:  Sunanda Basu; Hal E Broxmeyer
Journal:  Blood       Date:  2005-03-29       Impact factor: 22.113

7.  Alterations of mast cells and TGF-beta1 on the silymarin treatment for CCl(4)-induced hepatic fibrosis.

Authors:  Da-Hee Jeong; Gi-Ppeum Lee; Won-Il Jeong; Sun-Hee Do; Hai-Jie Yang; Dong-Wei Yuan; Ho-Yong Park; Kyu-Jong Kim; Kyu-Shik Jeong
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

8.  The role of activin A and Akt/GSK signaling in ovarian tumor biology.

Authors:  Thuy-Vy Do; Lena A Kubba; Monica Antenos; Alfred W Rademaker; Charles D Sturgis; Teresa K Woodruff
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

9.  TGF-beta1 attenuates mediator release and de novo Kit expression by human skin mast cells through a Smad-dependent pathway.

Authors:  Wei Zhao; Gregorio Gomez; Shao-Hua Yu; John J Ryan; Lawrence B Schwartz
Journal:  J Immunol       Date:  2008-11-15       Impact factor: 5.422

10.  Molecular insights on the effect of TGF-β1/-β3 in human corneal fibroblasts.

Authors:  Xiaoqing Guo; Audrey E K Hutcheon; James D Zieske
Journal:  Exp Eye Res       Date:  2016-03-16       Impact factor: 3.467

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.